JunB in multiple myeloma

• Project Number: WST3-F-5031298/002-2018
• Project Lead: Klaus Podar, Karl Landsteiner University of Health Sciences / Molecular Oncology / Hematology, Klaus Podar, Karl Landsteiner University of Health Sciences / Division of Internal Medicine 2 (University Hospital Krems)
• Project Partner: The Antibody Lab GmbH, IMC University of Applied Sciences Krems, University of Veterinary Medicine Vienna / Institute for Pharmacology and Toxicology
• Duration: 48 months starting from 01.10.2018

Background

This project is co-financed by the European Regional Development Fund (ERDF). For more information on IWB/EFRE, please visit www.efre.gv.at.
Microenvironment-induced signalling pathways regulate the activity of numerous transcription factors (TFs). Approaches targeting TFs are among the most promising new anticancer strategies with a potentially high therapeutic index. Our recent data suggest a key role of the AP-1 family member JunB in the pathogenesis of MM (Fan et al., Leukemia 2017). Following on from these findings, the proposed project aims to further define JunB as a novel therapeutic target in MM, setting the pace for the development of direct or indirect JunB inhibitors to further improve patient outcomes.